OXOA.F

Healthcare Biotechnology

Oxford Biomedica plc

€6.00

-0.30 -4.76% today

Price History

Not enough data

Key Stats

Market Cap

726.32M

Avg Volume

264

EPS

-€0.37

52W High

€10.90

52W Low

€4.64

Div. Yield

0.0%

Valuation

P/B Ratio

10.61

P/S Ratio

4.14

EV/EBITDA

-37.23

EV/Revenue

4.82

Margins

Gross Margin 36.2%

Operating Margin (26.8%)

Net Margin (23.2%)

EBITDA Margin (13.0%)

Growth & Returns

Revenue Growth (YoY)

9.0%

Return on Equity

(89.7%)

Return on Assets

(7.0%)

Liquidity & Leverage

Current Ratio

2.21

Quick Ratio

1.76

Debt / Equity

2.73

Total Cash

75.28M

Total Debt

158.64M

About

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.